Navigation Links
Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:12/15/2010

EAST BRUNSWICK, N.J., Dec. 15, 2010 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 11:00 a.m. Pacific Time.  The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.  

A live webcast of the presentation and the question and answer session can be accessed through the investor relations section of the Company's website www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase), which was approved by the FDA on September 14, 2010 for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist Kevin ... recently traveled to Boston, MA ... the 2015 Heart Rhythm Society conference. These scientific ... focus on the ideas, people and technology that ... is a hybrid, minimally invasive cardiac operation that ...
(Date:5/22/2015)... 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a ... and regeneration, today announced that J.J. Finkelstein , ... a corporate overview at two upcoming investor conferences. ... 4 th Annual Microcap Conference on Thursday May ... at 11:00 am EDT.  A webcast will be ...
(Date:5/22/2015)... May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... peer-reviewed publication of the results of the Company,s ... preservative-free eye drops) for the treatment of dry ... (CAE ® ) model.  The exploratory study was ... were previously disseminated by the Company in a ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... 22, 2011 Terso Solutions, Inc. has expanded its ... new refrigerator that is well-suited for hospital and ... the new refrigerator makes better use of space, reduces ... products such as reagents, cardiovascular products, tissue samples, and ...
... U.S. Food and Drug Administration today announced that Terumo ... two of its officers, Mark A. Sutter, president and ... Quality Assurance and Operations, have signed a consent decree ... ) The consent decree, to be ...
Cached Medicine Technology:Terso Solutions Launches New RFID-Enabled Refrigerator for Hospital and Laboratory Inventory Management 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 3
(Date:5/25/2015)... New York, New York (PRWEB) May 25, 2015 ... ( http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) continue to move forward in ... District Court, Northern District of Texas. According to ... have asked the Court to modify the Case ... Disclose Health Information. Among other things, the Motion ...
(Date:5/25/2015)... White Plains, NY (PRWEB) May 25, 2015 ... LEED AP, principal of PBDW Architects in New York City, ... which is part of the hospital’s ongoing Legacy Lobby Lecture ... campus in White Plains. White is the great grandson of ... firm responsible for the design of Burke’s campus 100 years ...
(Date:5/24/2015)... Dallas, TX (PRWEB) May 24, 2015 ... the Global and Chinese Enterokinase Industry, 2009-2019 Market Research ... as it is an exhaustive study on the present ... a special insight into the growing Chinese market of ... market and the overall status of the manufacturers in ...
(Date:5/24/2015)... ProPin is a set of self-animating ... Utilize ProPin to pin point locations on a map, to ... , ProPin allows users to choose from 30 simplistic presets with ... on-screen controls, video editors can easily manipulate ProPin presets as a ... with absolute ease. , Using ProPin is easy, simply drag a ...
(Date:5/23/2015)... City, FL (PRWEB) May 23, 2015 On ... to build a new playground for Branches Florida City exactly ... the former play space in 2010. , A large fire ... new playground on May 23, 2010 in the middle of ... watched. The fire was later declared arson even though it ...
Breaking Medicine News(10 mins):Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 2Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Five Years After Fire, Branches Rebuilds Playground 2
... The FDA approved Tibotec,Pharmaceutical,s novel non-nucleoside ... announced introductory pricing for,the eagerly anticipated new ... other recently introduced antiretrovirals., "The efficacy ... DUET,studies is impressive. INTELENCE is an important ...
... Protects Sensitive Customer Health Care ... Data on Laptops and ... a global,leader in enterprise data protection, today announced that Payformance,Health, ... Electronic Funds Transfer (EFT) and Electronic Remittance,Advice (ERA) services, has ...
... reveals Boomers feel young, but often ignore important, health issues; company ... ... ST. LOUIS, Jan. 31 Baby boomers are living,longer and leading ... it comes to long-term health. According to a,recent survey by Energizer Holdings, ...
... ... -- Revises 2008 EPS Guidance Primarily to Reflect the Sale of Medical ... Imaging, -- Reaffirms Expected Non-GAAP EPS CAGR of at ... Through 2010, Subject to Certain Assumptions, -- Completes Sale of Medical Imaging Business, Reports as Discontinued, ...
... PARK CITY, Utah, Jan. 31 Nutraceutical,International Corporation (Nasdaq: ... first quarter ended December 31, 2007. Net sales for ... $35.8 million for the,same quarter of fiscal 2007. For ... million, or $0.28 diluted earnings per share, compared to,net ...
... Canadian Regulatory Authorities Approve 3f(R) Aortic Bioprosthesis for Sale ... ... Company Updates Financial Outlook for 2008, MINNEAPOLIS, Jan. 31 ... products and services, today announced it has received a request,for additional information and ...
Cached Medicine News:Health News:Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE 2Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 2Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 3Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 4Health News:Boomers: Feeling Young or Fooling Themselves? 2Health News:Boomers: Feeling Young or Fooling Themselves? 3Health News:Boomers: Feeling Young or Fooling Themselves? 4Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 2Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 3Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 4Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 5Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 6Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 7Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 8Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 9Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 10Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 11Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 12Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 13Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 14Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 15Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 16Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 17Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 18Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 19Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 20Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 21Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 22Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 23Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 24Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 25Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 26Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 27Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 28Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 29
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
18 gauge tapered fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
Medicine Products: